Meeting
2020 ASCO Virtual Scientific Program
Pan-cancer analysis of FGFR1-3 genomic alterations to reveal a complex molecular landscape.
Authors
Melanie A. Krook
The Ohio State University Comprehensive Cancer Center, Ohio State University, Columbus, OH
Melanie A. Krook , Ian M. Silverman , Karthikeyan Murugesan , Gabrielle Ernst , Julie Reeser , Michele Wing , Garrett M. Frampton , Robert C Newton , Jeffery Richard Jackson , Lee A. Albacker , Timothy Burn , Sameek Roychowdhury
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3620)
DOI
10.1200/JCO.2020.38.15_suppl.3620
Abstract #
3620
Poster Bd #
350
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Landscape of fibroblast growth factor receptor (FGFR) genomic alterations (GA) in urothelial bladder cancer (UBC).
First Author: Maroun Bou Zerdan
Poster
2022 ASCO Genitourinary Cancers Symposium
Expanding the use of targeted therapy for urothelial bladder cancer (UBC): Non-FGFR3 receptor tyrosine kinase (RTK) gene rearrangements (ReAr) and fusions (fus).
First Author: Andrea Necchi
Poster
2019 ASCO Annual Meeting
Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).
First Author: Milind M. Javle
Poster
2018 ASCO Annual Meeting
Landscape of kinase rearrangements (kRE) detected in circulating tumor DNA (ctDNA).
First Author: Ben C. Creelan